Royalty Pharma (RPRX) Net Cash Flow (QoQ) (2019 - 2026)
Royalty Pharma (RPRX) Net Cash Flow (QoQ) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Royalty Pharma | 25.78 Bn | 28.22 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 89.91% |
| Dec 31, 2025 | -204.30% |
| Sep 30, 2025 | 167.36% |
| Jun 30, 2025 | -387.23% |
| Mar 31, 2025 | 854.75% |
| Dec 31, 2024 | 97.42% |
| Sep 30, 2024 | -188.38% |
| Jun 30, 2024 | 151.82% |
| Mar 31, 2024 | 179.66% |
| Dec 31, 2023 | 62.85% |
| Sep 30, 2023 | -726.50% |
| Jun 30, 2023 | -25.50% |
| Mar 31, 2023 | -63.16% |
| Dec 31, 2022 | 164.41% |
| Sep 30, 2022 | -452.71% |
| Jun 30, 2022 | 26.37% |
| Mar 31, 2022 | 196.42% |
| Dec 31, 2021 | -139.45% |
| Sep 30, 2021 | 51.92% |
| Jun 30, 2021 | 244.55% |